CN101804187B - Chinese traditional medicine composition for treating chronic ischemic cerebrovascular disease - Google Patents
Chinese traditional medicine composition for treating chronic ischemic cerebrovascular disease Download PDFInfo
- Publication number
- CN101804187B CN101804187B CN201010143880XA CN201010143880A CN101804187B CN 101804187 B CN101804187 B CN 101804187B CN 201010143880X A CN201010143880X A CN 201010143880XA CN 201010143880 A CN201010143880 A CN 201010143880A CN 101804187 B CN101804187 B CN 101804187B
- Authority
- CN
- China
- Prior art keywords
- cerebrovascular disease
- parts
- ischemic cerebrovascular
- medicine composition
- chronic ischemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a Chinese traditional medicine composition for treating chronic ischemic cerebrovascular disease. Aimed at the root cause of the development of the ischemic cerebrovascular disease, the invention chooses Chinese herbal medicines with the effects of tonifying Qi and invigorating the circulation of blood, dredging channels and collaterals and tonifying the liver and the spleen, including cassia twig, Chinese thorowax root, astragalus root, campanumaea pilosula, loranthus parasiticus, earthworm, drug sweetflag rhizome, dragon's teeth, sea-ear shell, dried ginger and akebia stem, which are scientifically prepared into the Chinese traditional medicine preparation which has a good curative effect on the chronic ischemic cerebrovascular disease and dos not have toxic sideeffect, so the Chinese traditional medicine composition is worth clinical popularization and application.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, especially relate to a kind of Chinese medicine composition for the treatment of chronic ischemic cerebrovascular disease.
Background technology
Ischemic cerebrovascular is a kind of commonly encountered diseases clinically, is meant because the cerebrovascular that a variety of causes causes stops up, and causes the cerebrovascular function obstacle, causes related symptoms, as hemiplegia, dysphonia, dizziness and tinnitus etc.At present, the treatment ischemic cerebrovascular removes rational diet, suitably takes exercise, discontinues the habit of smoking and drinking, when forming good life style, generally carry out Drug therapy, at present, it is more to treat this sick medicine, but the ubiquity therapeutic effect is poor, and the medicine that has is taken for a long time, and side effect is big.
Summary of the invention
Purpose of the present invention is exactly the root that forms at ischemic cerebrovascular, selection has the middle medicinal herbs of benefiting QI for activating blood circulation, collateral dredging passages through which vital energy circulates, tonifying liver spleen invigorating, through the science compatibility, that makes is a kind of good to the chronic ischemic cerebrovascular disease therapeutic effect, the Chinese medicine preparation that has no side effect.
The objective of the invention is to be achieved through the following technical solutions, the Chinese medicine composition of this treatment chronic ischemic cerebrovascular disease is made up of the crude drug of following weight fraction: Ramulus Cinnamomi 10-15 branch, Radix Bupleuri 10-15 branch, Radix Astragali 10-15 branch, Radix Codonopsis 5-10 branch, Herba Taxilli 5-10 branch, Pheretima 3-6 branch, Rhizoma Acori Graminei 3-6 branch, Dens Draconis 5-10 branch, Concha Haliotidis 3-6 branch, Rhizoma Zingiberis 10-15 branch, Caulis Akebiae 3-6 branch.
The crude drug that the Chinese medicine composition of this treatment chronic ischemic cerebrovascular disease is divided by following optimum weight is formed: Ramulus Cinnamomi 12 minutes, Radix Bupleuri 12 minutes, the Radix Astragali 13 minutes, Radix Codonopsis 8 minutes, Herba Taxilli 8 minutes, Pheretima 5 minutes, Rhizoma Acori Graminei 5 minutes, Dens Draconis 7 minutes, Concha Haliotidis 4 minutes, Rhizoma Zingiberis 13 minutes, Caulis Akebiae 4 minutes.
Preparation method: with above Chinese medicine routinely preparation method can be made into various dosage forms, as capsule, decoction etc.
In the side: Ramulus Cinnamomi promoting the flow of QI-blood by warming the meridian, activating YANG and prormoting functioning of QI; The Radix Codonopsis invigorating the spleen and replenishing QI, the spleen invigorating lung benefiting; The Radix Bupleuri reconciling superficies and interior, soothing the liver yang invigorating; Herba Taxilli: invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling; The Pheretima meridians that pass through; Rhizoma Acori Graminei is warded off and dirtyly has one's ideas straightened out, and controls anemofrigid-damp arthralgia; Throb with fear and calm the nerves in the Dens Draconis town, heat clearing away and restlessness relieving; The Concha Haliotidis suppressing the hyperactive liver to relieve the wind syndrome, YANG hyperactivity suppressing has hepatoprotective effect and significant anticoagulation; The Rhizoma Zingiberis warming spleen and stomach for dispelling cold, recuperating depleted YANG is promoted blood circulation, warming the lung to resolve fluid-retention; Caulis Akebiae pathogenic fire purging row, promoting blood circulation.
Clinical data
1, inclusion criteria: 1. the acute cerebrovascular disease history of attack is arranged, but do not have the performance of local nerve afunction near at least half a year; 2. have because the clinical symptoms of limitation or diffusivity nervous lesion; 3. nervus centralis funtion part, mild damage; 5. treatment there are enough compliances.
2, physical data: this is organized 206 routine patients and all meets above-mentioned standard.The main clinical manifestation of listing observation in has dizziness, headache, tinnitus, attention undiscipline, forgetful etc.Neuropsychological test adopts the scoring of simple intelligent status checkout scale.206 routine patients are divided into two groups at random.106 examples are organized in treatment, wherein male 76 examples, women 30 examples, 46 years old one 77 years old age, average 56.5 years old ± 16.2 years old, MMSE scoring 21.9 ± 8.1; Matched group 100 examples, wherein male 72 examples, women 28 examples, 48 years old one 78 years old age, average 58.9 years old ± 15.2 years old, MMSE scoring 22.0 ± 7.7.The processing there was no significant difference is learned in two groups of patient's physical data and clinical manifestation by statistics, sees Table 1.
Table 1 liang group patient's physical data and clinical manifestation situation
3, Therapeutic Method
Oral capsule of the present invention is organized in treatment, 60mg, 2 times/day, totally 8 weeks.The oral nimodipine sustained release capsules of matched group, 60mg, 2 times/day, totally 8 weeks.Blood test respectively, routine urinalysis and liver, renal function before and after all patient treatments.Write down untoward reaction simultaneously.
4, curative effect is judged
Produce effects: clinical symptom relief 80% one 96%; Effectively: clinical symptom relief 50% one 79%; Progressive: clinical symptom relief 30% one 49%; Invalid: clinical symptom relief less than 30%, increase the weight of or treat during have acute neurological deficit incident to take place.
5, statistical method
Data represents that with ± s statistical method adopts t check in groups, paired t-test) (2 checks and Ridit analyze etc.
6, therapeutic effect
Treatment group total effective rate is 90.6%, and the matched group total effective rate is 66%.Two groups of curative effects have significant differences (P＜0.01), see Table 2.The average MMSE scoring in treatment group treatment back obviously improves (P＜0.01) before the treatment, and average MMSE scoring also has raising (P＜0.05) before the treatment after the treatment of control group.Two groups of average MMSE scorings in treatment back are compared, and the treatment group sees Table 3 apparently higher than matched group (P＜0.01).Blood test behind two groups of patient treatments, urinalysis and liver, all no abnormal discovery of renal function.It is dizzy, nauseating that the treatment group has 5 examples to occur during medication, about 2 weeks back disappearance, and influence is treated.Dizzy, 6 examples of feeling sick that matched group occurs, flush, each 4 example of skin pruritus.
Clinical manifestation relatively behind the table 2 liang group patient treatment
| Group | The example number | Produce effects | Effectively | Progressive | Invalid | The R value |
| The treatment group | 106 | 46 | 40 | 10 | 10 | 0.3985 |
| Matched group | 100 | 18 | 28 | 20 | 34 | 0.6076 |
Annotate: two groups of treatment back mdit analyze P＜0.01
Average MMSE scoring relatively before and after the table 3 liang group patient treatment
| Time | The treatment group | Matched group |
| Before the treatment | 21.9±8.1 | 22.0±7.7 |
| After the treatment | 25.6±3.7 | 23.2±6.7 |
Annotate: with preceding relatively P＜0.01 of matched group that reaches of treatment; With preceding relatively P＜0.05 of treatment
The specific embodiment
Embodiment one: get Ramulus Cinnamomi 120 grams, Radix Bupleuri 120 grams, the Radix Astragali 130 grams, Radix Codonopsis 80 grams, Herba Taxilli 80 grams, Pheretima 50 grams, Rhizoma Acori Graminei 50 grams, Dens Draconis 70 grams, Concha Haliotidis 40 grams, Rhizoma Zingiberis 130 grams, Caulis Akebiae 40 grams.Pulverize separately, mix homogeneously incapsulates and gets final product.
Embodiment two: get Ramulus Cinnamomi 150 grams, Radix Bupleuri 100 grams, the Radix Astragali 100 grams, Radix Codonopsis 100 grams, Herba Taxilli 100 grams, Pheretima 30 grams, Rhizoma Acori Graminei 30 grams, Dens Draconis 100 grams, Concha Haliotidis 60 grams, Rhizoma Zingiberis 150 grams, Caulis Akebiae 30 grams.Pulverize separately, mix homogeneously incapsulates and gets final product.
Embodiment three: get Ramulus Cinnamomi 100 grams, Radix Bupleuri 150 grams, the Radix Astragali 150 grams, Radix Codonopsis 50 grams, Herba Taxilli 50 grams, Pheretima 60 grams, Rhizoma Acori Graminei 60 grams, Dens Draconis 50 grams, Concha Haliotidis 30 grams, Rhizoma Zingiberis 100 grams, Caulis Akebiae 60 grams.Pulverize separately, mix homogeneously incapsulates and gets final product.
Claims (2)
1. Chinese medicine composition for the treatment of chronic ischemic cerebrovascular disease, the Chinese medicine composition that it is characterized in that this treatment chronic ischemic cerebrovascular disease is made up of following bulk drugs: Ramulus Cinnamomi 10-15 part, Radix Bupleuri 10-15 part, Radix Astragali 10-15 part, Radix Codonopsis 5-10 part, Herba Taxilli 5-10 part, Pheretima 3-6 part, Rhizoma Acori Graminei 3-6 part, Dens Draconis 5-10 part, Concha Haliotidis 3-6 part, Rhizoma Zingiberis 10-15 part, Caulis Akebiae 3-6 part.
2. a kind of Chinese medicine composition for the treatment of chronic ischemic cerebrovascular disease according to claim 1, the Chinese medicine composition that it is characterized in that this treatment chronic ischemic cerebrovascular disease is made up of following bulk drugs: 12 parts of Ramulus Cinnamomis, 12 parts of Radix Bupleuri, 13 parts of the Radixs Astragali, 8 parts of Radix Codonopsis, 8 parts of Herba Taxillis, 5 parts of Pheretimas, 5 parts of Rhizoma Acori Gramineis, 7 parts of Dens Draconiss, 4 parts of Concha Haliotidis, 13 parts of Rhizoma Zingiberiss, 4 parts of Caulis Akebiaes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010143880XA CN101804187B (en) | 2010-04-04 | 2010-04-04 | Chinese traditional medicine composition for treating chronic ischemic cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010143880XA CN101804187B (en) | 2010-04-04 | 2010-04-04 | Chinese traditional medicine composition for treating chronic ischemic cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101804187A CN101804187A (en) | 2010-08-18 |
| CN101804187B true CN101804187B (en) | 2011-08-10 |
Family
ID=42606247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010143880XA Expired - Fee Related CN101804187B (en) | 2010-04-04 | 2010-04-04 | Chinese traditional medicine composition for treating chronic ischemic cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101804187B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102784A (en) * | 1994-02-28 | 1995-05-24 | 虹雨集团公司 | Chinese patent medicine for prevention and control of ischemic cardio-cerebral angiopathy |
| CN1726972A (en) * | 2004-07-31 | 2006-02-01 | 兰州佛慈制药股份有限公司 | Combination of medication in use for treating coronary heart disease and preparation method |
-
2010
- 2010-04-04 CN CN201010143880XA patent/CN101804187B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1102784A (en) * | 1994-02-28 | 1995-05-24 | 虹雨集团公司 | Chinese patent medicine for prevention and control of ischemic cardio-cerebral angiopathy |
| CN1726972A (en) * | 2004-07-31 | 2006-02-01 | 兰州佛慈制药股份有限公司 | Combination of medication in use for treating coronary heart disease and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 王守富等.活血化瘀13法在心脑血管疾病中的运用.《辽宁中医杂志》.2008,第35卷(第7期), * |
| 黄邦荣等.裴正学教授治疗脑血管意外经验.《甘肃中医》.2007,第20卷(第2期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101804187A (en) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103007059B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN102188685A (en) | Externally-applied traditional Chinese medicine powder for treating diarrhea type irritable bowel syndrome and preparation method thereof | |
| CN102626508B (en) | Traditional Chinese medicine composite for curing liver cancer | |
| CN1883640A (en) | Medicine for treating leucocytopenia caused after tumor radiotherapy and chemotherapy | |
| CN101804189B (en) | Drug for treating primary dysmenorrhea | |
| CN101361949A (en) | Traditional Chinese medicine for treating gynaecologic emmeniopathy | |
| CN112402522B (en) | Chinese herbal medicine oil for externally treating psoriasis | |
| CN104258362A (en) | Traditional Chinese medicine preparation for treating peripheral neuritis | |
| CN101804187B (en) | Chinese traditional medicine composition for treating chronic ischemic cerebrovascular disease | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN101099836B (en) | Traditional Chinese medicine composition for treating ischemic apoplexy and preparation process thereof | |
| CN101057945A (en) | Traditional Chinese medicine for treating digestive cancer and its producing method | |
| CN104606406B (en) | A kind of traditional Chinese medicinal ointment and preparation method thereof of external application prevention of allergic rhinitis | |
| CN106236857B (en) | Traditional Chinese medicine composition for treating chronic renal failure and preparation method, preparation and application thereof | |
| CN1270755C (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN103800561A (en) | Traditional Chinese medicine for treating renal hematuria | |
| CN111437378B (en) | Traditional Chinese medicine composition and medicine for preventing and treating chronic heart failure and preparation method thereof | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN101983645A (en) | Medicament for treating acute appendicitis | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| CN104758346A (en) | Medicine for treating migraine, as well as preparation method and preparation of medicine | |
| CN104274594B (en) | One is treated prosopalgic Chinese medicine preparation | |
| CN104667203A (en) | Medicine for treating coronary heart disease | |
| CN103301316B (en) | Traditional Chinese medicine composition for treating Intermin-gled phlegm and blood stasis syndrome globus hystericus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110810 Termination date: 20120404 |